Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 9/20 | 0.64 |
| ▸ | MAP3K6 | O95382 | 3/20 | 0.61 |
| ▸ | MAP3K5 | Q99683 | 3/20 | 0.61 |
| ▸ | LIMK2 | P53671 | 7/20 | 0.55 |
| ▸ | BTK | Q06187 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20641460 | 0.89 | MAP3K5 (0.59) | AKT1MAP3K6MAP3K5BTK | |
| SCHEMBL24805277 | 0.85 | AKT1 (0.53) | AKT1MAP3K6MAP3K5LIMK2 | |
| SCHEMBL20640493 | 0.82 | MAP3K5 (0.71) | AKT1MAP3K6MAP3K5LIMK2 | |
| SCHEMBL1001746 | 0.82 | CNR1 (0.50) | AKT1MAP3K6MAP3K5BTK | |
| SCHEMBL15456742 | 0.82 | AKT1 (0.54) | AKT1MAP3K6MAP3K5LIMK2 | |
| SCHEMBL28367843 | 0.81 | AKT1 (0.57) | AKT1LIMK2BTK | |
| SCHEMBL6832454 | 0.80 | ADRB2 (0.52) | AKT1MAP3K6MAP3K5BTK | |
| SCHEMBL24805938 | 0.80 | AKT1 (0.48) | AKT1MAP3K6MAP3K5LIMK2 | |
| SCHEMBL1005506 | 0.80 | KIT (0.60) | — | |
| SCHEMBL30151464 | 0.80 | KIT (0.60) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169653-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES | GALAPAGOS NV (BE) | 2022-06-02 | — | — | US | disclosed |
| US-20220169653-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES | GALAPAGOS NV (BE) | 2022-06-02 | — | — | US | disclosed |
| US-11136325-B2 | Pyrrolopyrimidine and pyrrolopyridine derivatives | GALAPAGOS NV (BE) | 2021-10-05 | — | — | US | disclosed |
| US-11136325-B2 | Pyrrolopyrimidine and pyrrolopyridine derivatives | GALAPAGOS NV (BE) | 2021-10-05 | — | — | US | disclosed |
| US-20200165259-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES | GALAPAGOS NV (BE) | 2020-05-28 | — | — | US | disclosed |
| US-20200165259-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES | GALAPAGOS NV (BE) | 2020-05-28 | — | — | US | disclosed |
| EP-3652173-A1 | ASK1 INHIBITING PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES | Galapagos NV (BE) | 2020-05-20 | — | — | EP | disclosed |
| CN-111094283-A | ASK 1-inhibiting pyrrolopyrimidine and pyrrolopyridine derivatives | 加拉帕戈斯股份有限公司 | 2020-05-01 | — | — | CN | disclosed |
| WO-2019012284-A1 | ASK1 INHIBITING PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES | GALAPAGOS NV (BE) | 2019-01-17 | — | — | WO | disclosed |
| WO-2019012284-A1 | ASK1 INHIBITING PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES | GALAPAGOS NV (BE) | 2019-01-17 | — | — | WO | disclosed |
| US-9585886-B2 | ASK1 inhibiting pyrrolopyrimidine derivatives | CALCHAN LIMITED (GB) | 2017-03-07 | — | — | US | disclosed |
| US-9585886-B2 | ASK1 inhibiting pyrrolopyrimidine derivatives | CALCHAN LIMITED (GB) | 2017-03-07 | — | — | US | disclosed |
| EP-2651417-B1 | ASK1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | CALCHAN LTD (GB) | 2016-11-30 | — | — | EP | disclosed |
| US-20160067251-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | GALAPAGOS NV (BE) | 2016-03-10 | — | — | US | disclosed |
| US-20160067251-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | GALAPAGOS NV (BE) | 2016-03-10 | — | — | US | disclosed |
| US-9045485-B2 | ASK 1 inhibiting pyrrolopyrimidine derivatives | Convergence Pharmaceuticals Limited (GB) | 2015-06-02 | — | — | US | disclosed |
| US-9045485-B2 | ASK 1 inhibiting pyrrolopyrimidine derivatives | Convergence Pharmaceuticals Limited (GB) | 2015-06-02 | — | — | US | disclosed |
| US-20140038957-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | Convergence Pharmaceuticals Limited | 2014-02-06 | — | — | US | disclosed |
| US-20140038957-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | Convergence Pharmaceuticals Limited | 2014-02-06 | — | — | US | disclosed |
| WO-2012080735-A1 | ASK1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | Convergence Pharmaceuticals Limited (GB) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200165259-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES | IRAK1, PEAK1, MARK1 | AKT1 2561/4885MAP3K6 33/4885MAP3K5 14/4885 |
| US-20160067251-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | YES1, IRAK1, TBK1 | AKT1 339/4885MAP3K6 14/4885MAP3K5 16/4885 |
| US-20140038957-A1 | ASK 1 INHIBITING PYRROLOPYRIMIDINE DERIVATIVES | YES1, IRAK1, TBK1 | AKT1 339/4885MAP3K6 14/4885MAP3K5 16/4885 |
| US-11136325-B2 | Pyrrolopyrimidine and pyrrolopyridine derivatives | IRAK1, PEAK1, MARK1 | AKT1 2561/4885MAP3K6 33/4885MAP3K5 14/4885 |
| US-20220169653-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES | IRAK1, PEAK1, MARK1 | AKT1 2561/4885MAP3K6 33/4885MAP3K5 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.